change downstream. The base evidence for efficacy of second-generation antipsychotics (SGAs) in maintenance treatment of bipolar disorder provides an example of when shortcomings in regulatory oversight can lead to distorted interpretations of evidence and potentially inappropriate prescribing patterns (Cipriani et al., 2014) . As a general pattern in such randomised controlled trials (RCTs), in the first phase of the study, acutely symptomatic patients are recruited and receive open-label treatment with an SGA (as monotherapy or as addon treatment to lithium or valproate). Patients who do not remit with an SGA are excluded, and only those who achieve stable remission are randomised to the second phase of the study, a double-blind treatment with the same SGA or placebo. Such enrichment design RCTs, therefore, represent continuation studies (i.e. they answer the question, 'How long should we continue the treatment that worked for a patient who was acutely ill?'), rather than pure maintenance studies ('What is the best treatment to be prescribed to a non-acutely ill patient in order to reduce the risk of relapse?'). As might be expected, such long-term trials demonstrate that the proportion of acutely symptomatic patients who remit with acute treatment may benefit from continuing the same treatment long term. This is quite different from claiming that a drug is effective in patients who are euthymic at baseline and need long-term treatment to reduce the risk of relapse -the property that clinicians and patients arguably seek in mood stabilisers. Unfortunately, prescribing labels tend to brush over this nuance; despite the well-known use of enrichment design RCTs, the indication on prescribing information sheets for SGAs is broadened to 'maintenance treatment' for bipolar disorder, with no attempt to qualify the enriched population in whom the drug was shown to have an effect in the study.
The described situation in the field of bipolar disorder research probably applies to psychiatry in general, and it ought to be addressed if we are to develop treatments that will eventually bring about better outcomes for our patients. It is essential that regulatory agencies, as gatekeepers to the approval and licensing of new treatments, adopt stricter definitions and a priori criteria that require more compelling evidence before a drug is approved. Regulators, industry and academia should work together in that direction because, ultimately, as long as drugs are granted approval, the arguments about design flaws and misleading labels, however convincing, will be of little impact. 
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The narrative review by Pfennig et al. (2017) episodes, (3) increasing symptomatic severity of episodes, (4) decreasing threshold for developing episodes, and (5) increasing risk of developing dementia (Kessing and Andersen, 2017) . In this way, psychopathology of each mood episode changes during the course of illness. Another example is that the prevalence of mixed features in women with bipolar disorder is much more prevalent later than in the first mood episodes in bipolar disorder (Kessing, 2008) . Second, the reason for this bidirectional association between psychopathology and biology is that bipolar disorder is partly genetic and biologically driven and partly driven by environmental stress of sociological and psychological origin. It is likely that the genetically related biology of bipolar disorder is changed by environmental factors (i.e. epigenetics) making patients more stress sensitive during the course of illness that results in behavioral sensitization, neuroprogression and changes in the psychopathology of affective disorders (Post, 2016) . Thus, the experience of mood episodes may change the biology of bipolar disorder and changed biology may result in changed psychopathology and clinical progression of the disorder. Taking such psychopathological and biological consequences into account it is striking how few prospective longitudinal studies have been undertaken. Although the review by Pfennig et al. did not conduct a systematic literature search, only 19 prospective studies on the early developmental course of bipolar disorder were identified covering antecedent and early stages of bipolar disorder. We have discussed the limitations of prior prospective longitudinal studies on the biology of bipolar disorder in a research protocol concluding that the results from these studies are hampered by a number of limitations (Kessing et al., in press ). Only few studies have recruited patients with bipolar illness from onset of the illness, the number of patients included is few, and the prospective follow-up periods are short, mostly less than a few years. In addition, as discussed in the research protocol, the inherent design of prospective longitudinal studies implies some challenges and limitations (Kessing et al., in press ). Often extensive initial assessment procedures may potentially result in selection of participants who are intrinsically positive toward clinical research and readily willing to cooperate. Attrition may increase during long-term follow-up and patients who stay in the study may adhere more to treatment in general. Furthermore, due to the observational design, it is not possible to avoid the potential confounding effects of psychotropic medication and other interventions and finally, due to the large number of biological and statistical tests included in such studies, chance findings may occur in relation to the individual biological test. Nevertheless, with a prospective, repeated measures design it is possible to identify associations between biology and depressive and manic symptoms and states, and fortunately a number of prospective longitudinal cohort studies on the psychopathology and biology early in bipolar disorder have started or are about to be initiated internationally.
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Psychiatry has always been a field in which the meaning of words has been particularly challenging. One might argue that the core mission of the modern Diagnostic and Statistical Manuals of Mental Disorders (DSMs), beginning with Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) in 1980, was to create a dictionary of diagnoses such that describing a patient's diagnosis as major depression would mean the same (reliability) to all clinicians and researchers, regardless of whether the definition was optimal (validity). In their recent editorial, Malhi et al. (2017) suggest that we rethink the meaning of the term 'mood stabilizer', proposing that we expand the definition from its usual current meaning of describing a treatment that (optimally)
